Ph3 palazestrant with ribociclib vs letrozole with ribociclib for 1L Tx ER+ HER2-adv BC
Phase III Clinical Trial
A phase 3 randomized double-blind active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+ HER2- advanced breast cancer (OPERA-02) OP-1250-302
Participating Locations